Journal
BLOOD ADVANCES
Volume 6, Issue 14, Pages 4216-4223Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2022007454
Keywords
-
Categories
Funding
- Foundation for Promotion of Cancer Research
- Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan
- Japanese Society for Hematology, the Program for the Development of Next-Generation Leading Scientists with Global Insight (L-INSIGHT)
Ask authors/readers for more resources
This study analyzed the coagulation/fibrinolysis parameters in DLBCL patients treated with tisagenlecleucel and found a hypofibrinolytic and relatively hypercoagulable state concomitant with elevated PAI-1 levels at the onset of CRS, which gradually resolved after CRS remission. These results contribute to the understanding of CRS-related coagulopathy and highlight the importance of monitoring coagulation/fibrinolysis parameters during CAR-T therapy.
Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related coagulopathy remain unknown. Therefore, we conducted a prospective cohort study to comprehensively analyze coagulation/fibrinolysis parameters present in peripheral blood of adult DLBCL patients treated with tisagenlecleucel in a single institution. Samples were collected from 25 patients at 3 time points: before lymphocyte-depletion chemotherapy and on days 3 and 13 after CAR-T infusion. After infusion, all patients except 1 experienced CRS, and 13 required the administration of tocilizumab. A significant elevation in the plasma level of total plasminogen activator inhibitor 1 (PAI-1), which promotes the initial step of coagulopathy (mean, 22.5 ng/mL before lymphocyte-depletion and 41.0 on day 3, P = .02), was observed at the onset of CRS. Moreover, this suppressed fibrinolysis-induced relatively hypercoagulable state was gradually resolved after CRS remission with normalization of total PAI-1 to preinfusion levels without any organ damage (mean values of soluble fibrin: 3.16 mg/mL at baseline, 8.04 on day 3, and 9.16 on day 13, P < .01; and mean PAI-1: 25.1 ng/mL on day 13). In conclusion, a hypofibrinolytic and relatively hypercoagulable state concomitant with significant total PAI-1 elevation was observed at the onset of CRS even in DLBCL patients with mild CRS. Our results will facilitate understanding of CRS-related coagulopathy, and they emphasize the importance of monitoring sequential coagulation/fibrinolysis parameters during CAR-T therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available